Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Friday.

Several other equities analysts have also weighed in on the stock. Stifel Nicolaus restated a “buy” rating and set a $35.00 price objective (down previously from $45.00) on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 17th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $18.00 target price (down from $21.00) on shares of Valeant Pharmaceuticals International in a report on Thursday, March 23rd. Deutsche Bank AG decreased their target price on shares of Valeant Pharmaceuticals International from $19.00 to $18.00 and set a “hold” rating for the company in a report on Wednesday, April 19th. Piper Jaffray Companies reiterated an “outperform” rating and issued a $10.00 target price on shares of Valeant Pharmaceuticals International in a report on Friday, April 14th. Finally, Scotiabank raised their target price on shares of Valeant Pharmaceuticals International from $12.00 to $14.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $16.26.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded up 1.81% on Friday, reaching $15.78. 33,454,476 shares of the company’s stock traded hands. The company has a 50 day moving average of $12.48 and a 200-day moving average of $12.90. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $32.74. The stock’s market capitalization is $5.49 billion. Valeant Pharmaceuticals International also was the recipient of some unusual options trading activity on Wednesday. Investors purchased 45,767 call options on the company. This represents an increase of approximately 165% compared to the typical volume of 17,246 call options.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $1.93. The firm had revenue of $2.11 billion during the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. Valeant Pharmaceuticals International’s revenue was down 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.08) EPS. Equities research analysts forecast that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Upgraded at BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/06/23/valeant-pharmaceuticals-international-inc-vrx-upgraded-at-bidaskclub.html.

In related news, Director Schutter Richard U. De acquired 20,000 shares of the stock in a transaction dated Thursday, May 11th. The shares were acquired at an average price of $13.90 per share, for a total transaction of $278,000.00. Following the completion of the purchase, the director now owns 70,572 shares in the company, valued at approximately $980,950.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.87% of the company’s stock.

Large investors have recently bought and sold shares of the company. Jennison Associates increased its stake in Valeant Pharmaceuticals International by 0.8% in the third quarter. Jennison Associates now owns 308,200 shares of the specialty pharmaceutical company’s stock worth $54,977,000 after buying an additional 2,364 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft increased its stake in Valeant Pharmaceuticals International by 6.6% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 73,800 shares of the specialty pharmaceutical company’s stock worth $12,732,000 after buying an additional 4,600 shares in the last quarter. Janus Capital Management increased its stake in Valeant Pharmaceuticals International by 36.1% in the third quarter. Janus Capital Management now owns 3,258,686 shares of the specialty pharmaceutical company’s stock worth $581,295,000 after buying an additional 863,566 shares in the last quarter. Gillespie Robinson & Grimm increased its stake in Valeant Pharmaceuticals International by 12.3% in the fourth quarter. Gillespie Robinson & Grimm now owns 123,815 shares of the specialty pharmaceutical company’s stock worth $12,586,000 after buying an additional 13,525 shares in the last quarter. Finally, Capstone Asset Management Company increased its stake in Valeant Pharmaceuticals International by 2.0% in the fourth quarter. Capstone Asset Management Company now owns 41,397 shares of the specialty pharmaceutical company’s stock worth $4,208,000 after buying an additional 813 shares in the last quarter. Hedge funds and other institutional investors own 50.45% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.